Cabozantinib

Overview

Cabozantinib is a c-Met inhibitor that is currently FDA approved for the treatment of patients with advanced renal cell carcinoma (RCC).

SparkCures ID 69
Developed By Exelixis
Generic Name Cabozantinib
Additional Names Cabometyx
Treatment Classifications
  • Bruton's Tyrosine Kinase (BTK) Inhibitor

Clinical Trials

Resources

There are no resources, links or videos to display for this treatment.